Early malaria vaccine trial halted – what we know
NCT ID NCT05270265
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a new vaccine against Plasmodium vivax malaria, given with an adjuvant to boost immune response. It involved 25 healthy adults in the UK to check safety and immune reactions. The study was terminated early, so full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pvs25-IMX313 vaccine with Matrix-M1 adjuvant
- What this could lead to
- If successful, this could help develop a vaccine against Plasmodium vivax malaria, a major cause of malaria outside Africa.
- What could go wrong
- This was a very early (Phase 1) trial that was terminated, so results are limited. The vaccine may not produce strong enough immunity or may have safety issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA VIVAX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CCVTM, University of Oxford, Churchill Hospital
Oxford, OX3 7LE, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can At-Home malaria pills work as well as supervised care?
- New malaria treatment plan put to the test in peru
- New malaria combo aims to stop relapses for good
- Malaria-Fighting drug given to entire villages shows promise
- Malaria elimination experiment: entire peruvian villages to receive mass drug dosing
- New malaria vaccine vivaxin enters first human tests